An Open-Label, Multicenter, Dose-Escalation, Phase I Study To Evaluate Safety, Pharmacokinetics, And Preliminary Anti-Tumor Activity Of Ro7444973 In Participants With Advanced And/Or Metastatic Mage A4-Positive, Solid Tumors.